TEMCELL Trademark

Trademark Overview

On Thursday, February 25, 2016, a trademark application was filed for TEMCELL with the United States Patent and Trademark Office. The USPTO has given the TEMCELL trademark a serial number of 79187856. The federal status of this trademark filing is CANCELLED - SECTION 71 as of Friday, July 28, 2023. This trademark is owned by JCR PHARMACEUTICALS CO., LTD.. The TEMCELL trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations containing mesenchymal stem cells as active ingredients for the treatment and prevention of inflammation, inflammatory diseases, auto-immune diseases, genetic disorders, and graft-versus-host disease
temcell

General Information

Serial Number79187856
Word MarkTEMCELL
Filing DateThursday, February 25, 2016
Status709 - CANCELLED - SECTION 71
Status DateFriday, July 28, 2023
Registration Number5121610
Registration DateTuesday, January 17, 2017
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 1, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations containing mesenchymal stem cells as active ingredients for the treatment and prevention of inflammation, inflammatory diseases, auto-immune diseases, genetic disorders, and graft-versus-host disease

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeF - NOT AVAILABLE
Class Status DateFriday, July 28, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameJCR PHARMACEUTICALS CO., LTD.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressJP
Party NameJCR PHARMACEUTICALS CO., LTD.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressJP
Party NameJCR PHARMACEUTICALS CO., LTD.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressJP

Trademark Events

Event DateEvent Description
Thursday, April 11, 2024TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Thursday, April 11, 2024INVALIDATION PROCESSED
Thursday, March 28, 2024TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, July 28, 2023CANCELLED SECTION 71
Monday, January 17, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Saturday, May 13, 2017FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, April 24, 2017FINAL DISPOSITION NOTICE SENT TO IB
Monday, April 24, 2017FINAL DISPOSITION PROCESSED
Monday, April 17, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Tuesday, January 17, 2017REGISTERED-PRINCIPAL REGISTER
Tuesday, November 1, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 1, 2016PUBLISHED FOR OPPOSITION
Wednesday, October 12, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, September 23, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, September 16, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, September 15, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, September 15, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, September 13, 2016ASSIGNED TO LIE
Tuesday, September 6, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, July 16, 2016REFUSAL PROCESSED BY IB
Friday, July 1, 2016APPLICATION FILING RECEIPT MAILED
Wednesday, June 29, 2016NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, June 29, 2016REFUSAL PROCESSED BY MPU
Wednesday, June 29, 2016NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Tuesday, June 28, 2016NON-FINAL ACTION WRITTEN
Monday, June 27, 2016ASSIGNED TO EXAMINER
Monday, June 27, 2016NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 23, 2016SN ASSIGNED FOR SECT 66A APPL FROM IB

Related Keywords

temcell diseases genetic immune auto disorders graft disease host versus inflammatory